691857-53-1

Upstream product

• 403-42-9 1-(4-fluorophenyl)ethanone 
• 1999-00-4 ethyl 3-(4'-fluorophenyl)-3-oxopropionate 
• 691857-46-2 ethyl 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylate 
• 366496-33-5 1,4-dibromo-2-fluoro-5-nitrobenzene 
• 1333340-14-9 ethyl 5-bromo-2-(4-fluorophenyl)-6-nitrobenzofuran-3-carboxylate 
• 691856-87-8 ethyl 2-(4-fluorophenyl)-5-isopropoxybenzofuran-3-carboxylate 
• 691856-86-7 ethyl 2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylate 
• 691857-51-9 ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate 
• 691857-07-5 ethyl 2-(4-fluorophenyl)-5-isopropoxy-6-nitrobenzofuran-3-carboxylate 
• 691857-52-0 ethyl 5-cyclopropyl-2-(4-fluorophenyl)-6-nitrobenzofuran-3-carboxylate 

Downstream Products

• 691857-55-3 C₂₀H₁₈FNO₇S₂ 
• 1383851-17-9 ethyl 5-cyclopropyl-2-(4-fluorophenyl)-6-[(methylsulfonyl)amino]-1-benzofuran-3-carboxylate 
• 1383853-13-1 4-{[5-cyclopropyl-2-(4-fluorophenyl)-3-(1H-imidazol-2-yl)-1-benzofuran-6-yl](methylsulfonyl)amino}butanoic acid 
• 1383853-15-3 5-{[5-cyclopropyl-2-(4-fluorophenyl)-3-(1H-imidazol-2-yl)-1-benzofuran-6-yl](methylsulfonyl)amino}pentanamide 
• 1383853-21-1 N-[5-cyclopropyl-2-(4-fluorophenyl)-3-(1H-imidazol-2-yl)-1-benzofuran-6-yl]-N-[2-(ethylsulfonyl)ethyl]methanesulfonamide 
• 1383853-35-7 4-{[5-cyclopropyl-2-(4-fluorophenyl)-3-(1H-imidazol-2-yl)-1-benzofuran-6-yl](methylsulfonyl)amino } butanamide 
• 1383853-36-8 N-[5-cyclopropyl-2-(4-fluorophenyl)-3-(1H-imidazol-2-yl)-1-benzofuran-6-yl]-N-(2-hydroxyethyl)methanesulfonamide 
• 1383853-68-6 N-[5-cyclopropyl-3-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)-2-(4-fluorophenyl)-1-benzofuran-6-yl]-N-(2-hydroxyethyl)methanesulfonamide 
• 1383853-70-0 N-[5-cyclopropyl-3-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)-2-(4-fluorophenyl)-1-benzofuran-6-yl]-N-[2-(methylsulfinyl)ethyl]methanesulfonamide 
• 1383851-18-0 ethyl 5-cyclopropyl-2-(4-fluorophenyl)-6-[(4-methoxybenzyl)(methylsulfonyl)amino]-1-benzofuran-3-carboxylate 
• 1383851-43-1 N-[5-cyclopropyl-2-(4-fluorophenyl)-3-(1H-imidazol-2-yl)-1-benzofuran-6-yl]-N-[3-(3-hydroxy-1,2-oxazol-5-yl)propyl]methanesulfonamide 
• 1383851-53-3 N-[5-cyclopropyl-2-(4-fluorophenyl)-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-benzofuran-6-yl]-N-(4-methoxybenzyl)methanesulfonamide 
• 1383851-54-4 N-{3-[4-(2-chloroethyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-5-cyclopropyl-2-(4-fluorophenyl)-1-benzofuran-6-yl}-N-(4-methoxybenzyl)methanesulfonamide 
• 1383851-55-5 N-[5-cyclopropyl-3-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)-2-(4-fluorophenyl)-1-benzofuran-6-yl]-N-(4-methoxybenzyl)methanesulfonamide 

Relevant academic research and scientific papers

Convergent Synthesis of the NS5B Inhibitor GSK8175 Enabled by Transition Metal Catalysis

A convergent eight-stage synthesis of the boron-containing NS5B inhibitor GSK8175 is described. The previous route involves 13 steps in a completely linear sequence, with an overall 10% yield. Key issues include a multiday SNAr arylation of a s

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

Conversion of a Benzofuran Ester to an Amide through an Enamine Lactone Pathway: Synthesis of HCV Polymerase Inhibitor GSK852A

HCV NS5B polymerase inhibitor GSK852A (1) was synthesized in only five steps from ethyl 4-fluorobenzoylacetate (3) in 46% overall yield. Key to the efficient route was the synthesis of the highly functionalized benzofuran core 15 from the β-keto ester in

HEPATITIS C INHIBITORS AND USES THEREOF

This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

COMBINATION THERAPY METHOD FOR TREATING HEPATITIS C VIRUS INFECTION AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN

Combination therapy methods for the treatment of hepatitis C virus infection and associated diseases, by the co-administration of 5-cyclopropyl-2- (4-fluoro-phenyl-6-[(2-hydroxy-ethyl)-methanesulfonyl-amino]-benzofuran- 3-carboxylic acid methylamide or a pharmaceutically acceptable salt thereof with natural, recombinant or modified interferon, that effectively inhibit viral replication.